According to the latest global cancer burden data report released by the International Agency for Research on Cancer (IARC), there will be approximately 4.530 million new cases of gastrointestinal cancer (GIC) and more than 1.444 million deaths worldwide in 2020. This means that, on average, 1 in 4 patients diagnosed with cancer is a GIC patient, and 1 in 3 cancer deaths should be due to GIC. Due to the inconvenience of early diagnosis of GIC, many patients are diagnosed at advanced stages. Accumulating evidence has demonstrated that diagnostic and prognostic biomarkers are useful to improve the diagnosis and prognosis of GIC.
Increasing studies have shown that tumorigenesis and metastasis are accompanied by a dysregulated expression of a large number of genes, including biomarkers, oncogenes, and tumor suppressors. However, the reason for the abnormal expression of these genes in GIC remains unclear.
This Research Topic aims to explore novel biomarkers for GIC, uncover the cause of GIC-related gene dysregulation, reveal the roles of oncogenes or tumor suppressors in gastrointestinal cancer, and other advances that deepen the understanding of gastrointestinal carcinogenesis and metastasis. All the conclusions are experimentally validated; for purely bioinformatic papers, either original instruments must be applied, or an unprecedented amount of data must be analyzed; studies based on a single database like TCGA without independent validation cannot be considered.
We, therefore, welcome the submission of Original Research Articles, Reviews, and Expert Opinions on themes including, but not limited to:
• Identification and molecular characterization of novel subtypes of GIC
• Novel diagnostic/prognostic biomarkers for GIC, including protein-coding genes and non-coding RNAs
• Novel strategies and tools for early screening and detection of GIC and Clinical Applications
• The role of dysregulated cellular signaling on GIC tumorigenesis or metastasis, such as epithelial-mesenchymal transition (EMT)
• The effects of mutation in the Coding Region or Noncoding Region on GIC tumorigenesis or metastasis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserve the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
According to the latest global cancer burden data report released by the International Agency for Research on Cancer (IARC), there will be approximately 4.530 million new cases of gastrointestinal cancer (GIC) and more than 1.444 million deaths worldwide in 2020. This means that, on average, 1 in 4 patients diagnosed with cancer is a GIC patient, and 1 in 3 cancer deaths should be due to GIC. Due to the inconvenience of early diagnosis of GIC, many patients are diagnosed at advanced stages. Accumulating evidence has demonstrated that diagnostic and prognostic biomarkers are useful to improve the diagnosis and prognosis of GIC.
Increasing studies have shown that tumorigenesis and metastasis are accompanied by a dysregulated expression of a large number of genes, including biomarkers, oncogenes, and tumor suppressors. However, the reason for the abnormal expression of these genes in GIC remains unclear.
This Research Topic aims to explore novel biomarkers for GIC, uncover the cause of GIC-related gene dysregulation, reveal the roles of oncogenes or tumor suppressors in gastrointestinal cancer, and other advances that deepen the understanding of gastrointestinal carcinogenesis and metastasis. All the conclusions are experimentally validated; for purely bioinformatic papers, either original instruments must be applied, or an unprecedented amount of data must be analyzed; studies based on a single database like TCGA without independent validation cannot be considered.
We, therefore, welcome the submission of Original Research Articles, Reviews, and Expert Opinions on themes including, but not limited to:
• Identification and molecular characterization of novel subtypes of GIC
• Novel diagnostic/prognostic biomarkers for GIC, including protein-coding genes and non-coding RNAs
• Novel strategies and tools for early screening and detection of GIC and Clinical Applications
• The role of dysregulated cellular signaling on GIC tumorigenesis or metastasis, such as epithelial-mesenchymal transition (EMT)
• The effects of mutation in the Coding Region or Noncoding Region on GIC tumorigenesis or metastasis
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserve the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
